Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX
- Etrasimod 2 mg treatment group achieved statistical significance in the percentage change in weekly peak pruritis (PP-NRS), in the change in Dermatology Life Quality Index (DLQI), and in the change in Patient-Oriented Eczema Measure (POEM) - Etrasimod 2 mg was generally well tolerated, consistent
View HTML
Toggle Summary Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
- Company highlights dedication to patients, employees, the community, the environment, and shareholders through initiatives focused on responsibility and sustainability, diversity and inclusion, and patient commitment PARK CITY, Utah --(BUSINESS WIRE)--Apr. 19, 2021-- Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
-Data presentation to be released online at 10:00 AM ET on Friday, April 23, 2021 -Live Q&A session with presenter to be held on Saturday, April 24, 2021 at 3:00 PM ET   PARK CITY, Utah --(BUSINESS WIRE)--Apr. 19, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARK CITY, Utah --(BUSINESS WIRE)--Apr. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2021 , the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 50,785 shares of its common
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARK CITY, Utah --(BUSINESS WIRE)--Mar. 19, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units
View HTML
Toggle Summary Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
- Olorinab investigated in three doses, 10 mg, 25 mg, and 50 mg, for abdominal pain associated with IBS-C & IBS-D - Trial did not meet primary endpoint in broad study population - Moderate to severe pain population at 50 mg showed statistically significant, clinically meaningful improvement vs
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Feb. 18, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021 , the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common
View HTML
Toggle Summary Arena Pharmaceuticals Announces Changes to Board of Directors
- Industry veteran Garry Neil , MD, named Board Chair - Nawal Ouzren, CEO of Sensorion named to Board SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil , MD, has been appointed Chair of the
View HTML
Toggle Summary Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial
– Evaluating 2 mg etrasimod in study participants with moderately-to-severely active ulcerative colitis (UC) – Topline data from ELEVATE UC 12 and UC 52 trials remain on track for Q1 2022 – Significant unmet need for safe and effective oral therapies in UC for patients with inadequate response,
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Jan. 22, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 16,950 shares of its common
View HTML